EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Same-day versus rapid ART initiation in HIV-positive individuals presenting with symptoms of tuberculosis: Protocol for an open-label randomized non-inferiority trial in Lesotho and Malawi

Felix Gerber iD, Robina Semphere, Blaise Lukau, Palesa Mahlatsi, Timeo Mtenga, Tristan Lee, Maurus Kohler, Tracy Renée Glass, Alain Amstutz, Mamello Molatelle, Peter MacPherson iD, Nthuseng Bridgett Marake und 4 weitere

PLOS ONE · 08.02.2024 · 19 (2) · e0288944

DOI: 10.1371/journal.pone.0288944 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, online erschienen am 08.02.2024. Verfasst von Felix Gerber und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, Tuberculosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background In absence of contraindications, same-day initiation (SDI) of antiretroviral therapy (ART) is recommended for people testing HIV-positive who are ready to start treatment. Until 2021, World Health Organization (WHO) guidelines considered the presence of TB symptoms (presumptive TB) a contraindication to SDI due to the risk of TB-immune reconstitution inflammatory syndrome (TB-IRIS). To reduce TB-IRIS risk, ART initiation was recommended to be postponed until results of TB investigations were available, and TB treatment initiated if active TB was confirmed. In 2021, the WHO guidelines changed to recommending SDI even in the presence of TB symptoms without awaiting results of TB investigations based on the assumption that TB investigations often unnecessarily delay ART initiation, increasing the risk for pre-ART attrition from care, and noting that the clinical relevance of TB-IRIS outside the central nervous system remains unclear. However, this guideline change was not based on conclusive evidence, and it remains unclear whether SDI of ART or TB test results should be prioritized in people with HIV (PWH) and presumptive TB. Design and methods SaDAPT is an open-label, pragmatic, parallel, 1:1 individually randomized, non-inferiority trial comparing two strategies for the timing of ART initiation in PWH with presumptive TB (“ART first” versus “TB results first”). PWH in Lesotho and Malawi, aged 12 years and older (re)initiating ART who have at least one TB symptom (cough, fever, night sweats or weight loss) and no signs of intracranial infection are eligible. After a baseline assessment, participants in the “ART first” arm will be offered SDI of ART, while those in the “TB results first” arm will be offered ART only after active TB has been confirmed or refuted. We hypothesize that the “ART first” approach is safe and non-inferior to the “TB results first” approach with regard to HIV viral suppression (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsTuberculosisHumansLesothoMalawiRandomized Controlled Trials as TopicEquivalence Trials as TopicPragmatic Clinical Trials as Topic

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
  • Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
  • University of Basel, Basel, Switzerland.
  • Helse Nord Tuberculosis Initiative, Kamuzu University of Health Sciences, Blantyre, Malawi.
  • SolidarMed Lesotho, Maseru, Lesotho.
  • Oslo Center for Biostatistics and Epidemiology, Oslo University Hospital, University of Oslo, Oslo, Norway.

ORCID-Profile: Felix Gerber, Peter MacPherson, Marriot Nliwasa

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Gerber, F., Semphere, R., Lukau, B., Mahlatsi, P., Mtenga, T., Lee, T., Kohler, M., Glass, T. R., Amstutz, A., Molatelle, M., MacPherson, P., Marake, N. B., Nliwasa, M., Ayakaka, I., Burke, R., & Labhardt, N. (2024). Same-day versus rapid ART initiation in HIV-positive individuals presenting with symptoms of tuberculosis: Protocol for an open-label randomized non-inferiority trial in Lesotho and Malawi. PLOS ONE, 19(2), e0288944. https://doi.org/10.1371/journal.pone.0288944

Vancouver

Gerber F, Semphere R, Lukau B, Mahlatsi P, Mtenga T, Lee T, et al. Same-day versus rapid ART initiation in HIV-positive individuals presenting with symptoms of tuberculosis: Protocol for an open-label randomized non-inferiority trial in Lesotho and Malawi. PLOS ONE. 2024;19(2):e0288944. doi:10.1371/journal.pone.0288944

BibTeX
@article{Gerber2024,
  author = {Gerber, Felix and Semphere, Robina and Lukau, Blaise and Mahlatsi, Palesa and Mtenga, Timeo and Lee, Tristan and Kohler, Maurus and Glass, Tracy Renée and Amstutz, Alain and Molatelle, Mamello and MacPherson, Peter and Marake, Nthuseng Bridgett and Nliwasa, Marriot and Ayakaka, Irene and Burke, Rachael and Labhardt, Niklaus},
  title = {Same-day versus rapid ART initiation in HIV-positive individuals presenting with symptoms of tuberculosis: Protocol for an open-label randomized non-inferiority trial in Lesotho and Malawi},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {2},
  pages = {e0288944},
  doi = {10.1371/journal.pone.0288944}
}
Kostenlos starten →